2007-2008

This page in English

2008

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.
Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al
Arthritis Rheum. 2008 Oct;59(10):1371-7

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.
Emery P, Keystone E, Tony H, Cantagrel A, van Vollenhoven R, Sanchez A, et al
Ann. Rheum. Dis. 2008 Nov;67(11):1516-23

"CD20 epitope masking by rituximab: Comment on the article by Gunnarsson et al - reply"
Gunnarsson I, Jónsdóttir T, van Vollenhoven R
Arthritis and Rheumatism. 2008 Feb;58(2):634

Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases.
Lu T, Jónsdóttir T, Jonsdottir T, van Vollenhoven R, Isenberg D
Ann. Rheum. Dis. 2008 Oct;67(10):1493-4

Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis.
Karonitsch T, Aletaha D, Boers M, Bombardieri S, Combe B, Dougados M, et al
Ann. Rheum. Dis. 2008 Oct;67(10):1365-73

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Keystone E, Heijde D, Mason D, Landewé R, Vollenhoven R, Combe B, et al
Arthritis Rheum. 2008 Nov;58(11):3319-29

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.
Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al
Ann. Rheum. Dis. 2008 Oct;67(10):1360-4

Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial.
Cardiel M, Tumlin J, Furie R, Wallace D, Joh T, Linnik M, et al
Arthritis Rheum. 2008 Aug;58(8):2470-80

Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index.
Petri M, Kasitanon N, Lee S, Link K, Magder L, Bae S, et al
Arthritis Rheum. 2008 Jun;58(6):1784-8

Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response.
Petri M, Kasitanon N, Singh S, Link K, Magder L, Bae S, et al
Arthritis Rheum. 2008 Jun;58(6):1789-95

The Janus of lupus--benefits and risks with B-cell therapy.
van Vollenhoven R
Lupus 2008 May;17(5):447-9

Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study.
Hanly J, Urowitz M, Su L, Sanchez-Guerrero J, Bae S, Gordon C, et al
Arthritis Rheum. 2008 May;59(5):721-9

Rheumatologists, take heart! We may be doing something right.
van Vollenhoven R
Arthritis Res. Ther. 2008 ;10(2):105

Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
van Vollenhoven R,
Rheumatology (Oxford) 2008 Jul;47(7):1106-7; author reply 1107

Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study.
Hanly J, Urowitz M, Siannis F, Farewell V, Gordon C, Bae S, et al
Arthritis Rheum. 2008 Mar;58(3):843-53

Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort.
Urowitz M, Gladman D, Ibañez D, Fortin P, Sanchez-Guerrero J, Bae S, et al
Arthritis Rheum. 2008 Feb;59(2):176-80

Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial.
van der Heijde D, Landewé R, van Vollenhoven R, Fatenejad S, Klareskog L
Ann. Rheum. Dis. 2008 Sep;67(9):1267-70

Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
Mathsson L, Mullazehi M, Wick M, Sjöberg O, van Vollenhoven R, Klareskog L, et al
Arthritis Rheum. 2008 Jan;58(1):36-45

Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis.
Emery P, McInnes I, van Vollenhoven R, Kraan M
Rheumatology (Oxford) 2008 Apr;47(4):392-8

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response.
Jónsdóttir T, Gunnarsson I, Risselada A, Henriksson E, Klareskog L, van Vollenhoven R
Ann. Rheum. Dis. 2008 Mar;67(3):330-4

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.
Bertsias G, Ioannidis J, Boletis J, Bombardieri S, Cervera R, Dostal C, et al
Ann. Rheum. Dis. 2008 Feb;67(2):195-205

Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE.
van Vollenhoven R, Klareskog L
Scand. J. Rheumatol. ;36(6):418-23

2007

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
Keystone E, Fleischmann R, Emery P, Furst D, van Vollenhoven R, Bathon J, et al
Arthritis Rheum. 2007 Dec;56(12):3896-908

Skewed distribution of proinflammatory CD4+CD28null T cells in rheumatoid arthritis.
Fasth A, Snir O, Johansson A, Nordmark B, Rahbar A, Af Klint E, et al
Arthritis Res. Ther. 2007 ;9(5):R87

Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort.
Urowitz M, Gladman D, Ibañez D, Fortin P, Sanchez-Guerrero J, Bae S, et al
Lupus 2007 ;16(9):731-5

Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue.
van Vollenhoven R
Ann. Rheum. Dis. 2007 Jul;66(7):849-51

Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis.
Augustsson J, Eksborg S, Ernestam S, Gullström E, van Vollenhoven R
Ann. Rheum. Dis. 2007 Nov;66(11):1462-6

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson S, Henriksson E, van Vollenhoven R
Arthritis Rheum. 2007 Apr;56(4):1263-72

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.
Askling J, Fored C, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al
Ann. Rheum. Dis. 2007 Oct;66(10):1339-44

Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study.
Hanly J, Urowitz M, Sanchez-Guerrero J, Bae S, Gordon C, Wallace D, et al
Arthritis Rheum. 2007 Jan;56(1):265-73

Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.
Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, et al
Clin. Immunol. 2007 Jan;122(1):62-74

Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes.
Landewé R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S
Arthritis Rheum. 2006 Oct;54(10):3119-25

InflammationReumatologi